Honoured to win Best Presentation at the 2025 SABR Consortium 🙌 Our 2-centre study showed single-fraction (34 Gy) SABR for early-stage NSCLC achieves equivalent outcomes & toxicity to 3-fraction schedules — with major benefits for patients & the environment. Findings align

Every 90 minutes, someone in the UK is diagnosed with neuroendocrine cancer — around 6,000 each year. Maybe it’s you. Maybe it’s someone you love. Maybe it’s someone still waiting for answers. Tomorrow is #WorldNeuroendocrineCancerDay - help us raise awareness and shine a light

📈 Neuroendocrine cancer incidence has risen 371% (1995–2018) - yet awareness remains low. We must do more to recognise and diagnose it earlier. 🔗 Learn more about neuroendocrine cancer: https://t.co/VefePiAe63

Please share this far and wide to support anybody affected with a malignant pleural effusion @BTOGORG @BTSrespiratory @UKPleura @CRUK_Policy @Roy_Castle_Lung @RuthStraussFdn @ALKPositiveinc @EgfrUk @asthmalunguk @Mesouk

Huge number of people to thank in this work and all listed on the team page @d33pan @chriscraig872 @jenjonesuk @SelinaTsim @YCGaryLee and many many others Update sponsored by @Rocket_Medical & delivered by One Vision Health

Updated with the latest evidence and guidelines and new sections to the website like ‘living with an IPC’ informed by qualitative research from Deepan Sivakumar & colleagues at GSTT

MY PLEURAL EFFUSION JOURNEY UPGRADE LAUNCH https://t.co/V4CAvnJEwp A decision support tool, designed by patients, to support anyone with a malignant pleural effusion understand the different interventions to help their breathlessness

https://t.co/OAkW8Vpix3 @BTSrespiratory @AshOrg @BTOGORG @asthmalunguk @RCPhysicians @COPDdoc @SmokeHistoryGM @IASLC @mahdi_iarc @RachM_UoN

In this editorial with @RuthSharrock6 & Arran Woodhouse we explore the journey of inpatient tobacco dependency treatment, review this study and consider how we can do more to address deeply entrenched social injustice through opt out models of tobacco treatment in all healthcare

NHS England should be proud of its national inpatient tobacco dependency treatment service & a recently published study in @ThoraxBMJ confirms how this programme is addressing entrenched injustices driven by tobacco. But these services are at risk & we must fight for them

https://t.co/fvbAkEsWrO @tb_doc @ZoeMerchantOT @lucygoss @pompili_cecilia @prehab4cancer @BTOGORG @BTSrespiratory @IASLC @GM_Cancer

4. • Prehabilitation should start while patients are being investigated for lung cancer. • Prehabilitation in curative settings has key differences to palliative settings

3. Highlights • Evidence of efficacy for prehabilitation in lung cancer continues to grow. • ‘Distributive justice’ requires equal treatment for all patients with lung cancer. • Prehabilitation should be delivered equitably and be stage and treatment-agnostic.

2. In this paper with colleagues across the country, we present the evidence & argument for treatment & stage agnostic prehab for all patients with lung cancer preparing for treatment

1. Prehabilitation for patients with #lungcabcer Everyday we the beneficial impact prehabilitation has for patients with lung cancer preparing for treatment, delivered by the brilliant prehab4cancer team in Greater Manchester led by Jack Murphy

6. Brillant to see all the work going on in the area of earlier diagnosis of symptomatic lung cancer @BTOGORG @BTSrespiratory @RCRadiologists @GM_Cancer

5. We also demonstrate a simple decision tree algorithm & a structured query language (SQL) based natural language processing (NLP) tool can both provide scalable & standardised options to categorise CXR requests & identify those that fulfil NG12 criteria https://t.co/EuvAgBm8bK

4. In our paper published today: if, in the future, we do move to a ‘CT-first’ approach we estimate a third of primary care CXR requests would be eligible for a CT based on NiCE criteria (NG12) and would equate to over half a million additional CT scans per year.

3. This is an important question to answer for the future of symptomatic lung cancer diagnosis. @MFTnhs we’re delighted to have recruited our 1st patients to the MEDLEY study this week, led by a brilliant team in Leeds https://t.co/Lfh9aOkLlr

2. The NPV is so high because the prevalence of lung cancer in this cohort is very low (1.4% diagnosed within 2 years). Plus, a CT-first approach could use a substantial and limited resource with numerous additional incidental findings questioning cost-effectiveness.